阳光诺和中标盐酸利多卡因项目券商看好助力业绩增长

自选股中标信息2025-07-24

2025年07月24日，据天眼查数据，晋城海斯制药有限公司盐酸利多卡因注射液一致性评价研究服务商选用谈判采购结果公告显示，中标方为阳光诺和（sh688621），招标方为晋城海斯制药有限公司。近半年内，阳光诺和获得8家券商积极评价：中泰证券和华安证券给予"买入"评级。浙商证券和华西证券给予"增持"评级。阳光诺和主营业务涵盖药学研究服务（占比约51.80%），临床试验及生物分析服务（占比约47.44%...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553070232?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-24 19:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2553070232","market":"sh","top_or_hot":-1,"title":"阳光诺和中标盐酸利多卡因项目 券商看好助力业绩增长","media":"自选股中标信息","content":"<div>\n<p>2025年07月24日，据天眼查数据，晋城海斯制药有限公司盐酸利多卡因注射液一致性评价研究服务商选用谈判采购结果公告显示，中标方为阳光诺和（sh688621），招标方为晋城海斯制药有限公司。近半年内，阳光诺和获得8家券商积极评价：中泰证券和华安证券给予\"买入\"评级。浙商证券和华西证券给予\"增持\"评级。阳光诺和主营业务涵盖药学研究服务（占比约51.80%），临床试验及生物分析服务（占比约47.44%...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724192504a6bf9b13&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阳光诺和中标盐酸利多卡因项目 券商看好助力业绩增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阳光诺和中标盐酸利多卡因项目 券商看好助力业绩增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-24 19:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724192504a6bf9b13&s=b><strong>自选股中标信息</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年07月24日，据天眼查数据，晋城海斯制药有限公司盐酸利多卡因注射液一致性评价研究服务商选用谈判采购结果公告显示，中标方为阳光诺和（sh688621），招标方为晋城海斯制药有限公司。近半年内，阳光诺和获得8家券商积极评价：中泰证券和华安证券给予\"买入\"评级。浙商证券和华西证券给予\"增持\"评级。阳光诺和主营业务涵盖药学研究服务（占比约51.80%），临床试验及生物分析服务（占比约47.44%...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724192504a6bf9b13&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724192504a6bf9b13&s=b","article_id":"2553070232","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724192504a6bf9b13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2553070232","pubTimestamp":1753356302,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年07月24日，据天眼查数据，晋城海斯制药有限公司盐酸利多卡因注射液一致性评价研究服务商选用谈判采购结果公告显示，中标方为阳光诺和，招标方为晋城海斯制药有限公司。近半年内，阳光诺和获得8家券商积极评价：中泰证券和华安证券给予\"买入\"评级。阳光诺和主营业务涵盖药学研究服务，临床试验及生物分析服务，权益分成，其他收入之和。截至发稿，阳光诺和股价报54.85元，下跌0.4%，成交额至3.04亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688621":"阳光诺和","BK0216":"研究试验"},"translate_title":"Sunshine Nuohe wins the bid for lidocaine hydrochloride project, brokerages are optimistic about boosting performance growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688621":1},"content_text":"2025年07月24日，据天眼查数据，晋城海斯制药有限公司盐酸利多卡因注射液一致性评价研究服务商选用谈判采购结果公告显示，中标方为阳光诺和（sh688621），招标方为晋城海斯制药有限公司。近半年内，阳光诺和获得8家券商积极评价：中泰证券和华安证券给予\"买入\"评级。浙商证券和华西证券给予\"增持\"评级。阳光诺和主营业务涵盖药学研究服务（占比约51.80%），临床试验及生物分析服务（占比约47.44%），权益分成（占比约0.61%），其他收入之和（占比约0.15%）。截至发稿，阳光诺和股价报54.85元，下跌0.4%，成交额至3.04亿元（5日均值3.29亿元）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553070232","isCrawlerRequest":true}

阳光诺和中标盐酸利多卡因项目 券商看好助力业绩增长

精彩评论

阳光诺和中标盐酸利多卡因项目券商看好助力业绩增长